Theralink Technologies, Inc. (THER) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerTheralink Technologies, Inc. (THER) trades at $0.0001. Theralink Technologies, Inc. is a commercial-stage precision medicine company developing novel cancer immunotherapy products and providing molecular data. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for THER: THER does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Theralink Technologies, Inc. (THER) Healthcare & Pipeline Overview
Theralink Technologies, Inc. is a commercial-stage biotechnology firm leveraging a patented phosphoprotein and protein biomarker platform to provide precision oncology data. Its Theralink Reverse Phase Protein Array assays assist biopharmaceutical companies and clinicians in identifying patient responders to cancer therapies, positioning it within the evolving precision medicine landscape.
What Is the Investment Thesis for THER?
Theralink Technologies, Inc. presents an investment profile centered on its commercial-stage precision oncology platform, offering molecular data crucial for personalized cancer treatment. The company's patented phosphoprotein and protein biomarker platform and Theralink Reverse Phase Protein Array assays address a significant market need by identifying drug responders and non-responders, potentially enhancing therapeutic efficacy and reducing healthcare costs. With a robust gross margin of 79.2%, the company demonstrates strong unit economics at the product level, indicating potential for profitability upon scaling operations and increasing revenue. Key growth catalysts include broader adoption of its assays by biopharmaceutical companies for clinical trials and drug development, as well as increased integration into clinical oncology practices. However, the company's current market capitalization of $0.00B and a substantial negative profit margin of -5093.6% highlight its early commercialization stage and significant operational burn rate. The high beta of 8.99 also suggests considerable volatility and sensitivity to market movements, characteristic of developing biotechnology firms. Investors evaluating Theralink must weigh the long-term potential of its precision medicine technology against its current financial challenges and the inherent risks of a high-growth, pre-profitability biotech company.
Based on FMP financials and quantitative analysis
THER Key Highlights
Commercial-stage operations focused on precision oncology, indicating active market engagement and revenue generation from its molecular data services.
- Gross Margin of 79.2%, demonstrating strong profitability at the product level and efficient cost management for its specialized assays.
- Significant negative Profit Margin of -5093.6%, reflecting substantial operational expenses and investment in R&D and commercialization typical of early-stage biotechnology companies.
- Market Capitalization of $0.00B, suggesting a relatively small valuation and potential for significant growth if commercialization efforts succeed.
- Beta of 8.99, indicating extremely high volatility and sensitivity to broader market fluctuations, characteristic of a high-risk, high-reward investment in the biotechnology sector.
Who Are THER's Competitors?
THER is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | +1.12% | $218M | 73 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 68 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are THER's Key Strengths?
Patented phosphoprotein and protein biomarker platform provides a unique technological advantage in precision oncology.
- Commercial-stage operations indicate existing market presence and revenue generation from its specialized assays.
- High gross margin of 79.2% suggests strong unit economics and potential for profitability at scale.
- Addresses a critical need in oncology by identifying drug responders and non-responders, aiding personalized medicine.
- Experienced leadership with CEO Michael I. Ruxin managing a focused team of 16 employees.
What Are THER's Weaknesses?
Significant negative profit margin of -5093.6% indicates substantial operational losses and high cash burn.
- Small market capitalization of $0.00B suggests limited financial resources and market liquidity.
- High beta of 8.99 points to extreme stock price volatility and sensitivity to market sentiment.
- Operates as an OTC Other stock, implying lower transparency and higher investment risk.
- Reliance on successful commercialization and adoption of its assays in a competitive biotech market.
What Are the Key Risks for THER?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant negative profit margin of -5093.6% indicates substantial operational losses and a high cash burn rate, posing a risk to long-term financial viability without further funding.
- High beta of 8.99 suggests extreme stock price volatility, exposing investors to substantial capital risk and making the stock highly sensitive to market downturns.
- Trading on the OTC Other market with an 'Unknown' disclosure status implies limited transparency, liquidity, and regulatory oversight, increasing investment risk.
- Intense competition from larger, well-funded biotechnology and diagnostic companies that may have greater resources for R&D, marketing, and market penetration.
- Dependence on successful clinical validation and market acceptance of its specialized assays, as failure to demonstrate clear utility could hinder commercialization efforts and revenue growth.
What Threats Does THER Face?
- Intense competition from larger, more established diagnostic and biotechnology companies.
- Regulatory hurdles and lengthy approval processes for new diagnostic tests and immunotherapy products.
- Rapid technological advancements by competitors could render current technologies less competitive.
- Challenges in securing adequate funding and capital to sustain operations and fuel growth.
- Dependence on successful clinical validation and market acceptance of its specialized assays.
What Are THER's Competitive Advantages?
- Patented phosphoprotein and protein biomarker platform, offering unique insights into cellular signaling pathways relevant to cancer.
- Proprietary Theralink Reverse Phase Protein Array (RPPA) assay technology, providing a specialized method for molecular profiling.
- Expertise in generating precision oncology data, which is critical for identifying drug responders and non-responders.
- Early commercial-stage presence in a specialized niche of precision medicine, allowing for potential first-mover advantages in specific applications.
- Focus on actionable information for physicians, patients, and biopharmaceutical companies, addressing a clear unmet need in personalized cancer care.
What Does THER Do?
Theralink Technologies, Inc., headquartered in Golden, Colorado, operates as a commercial-stage precision medicine and molecular data-generating company focused on the development and commercialization of novel cancer immunotherapy products. The company's foundational technology centers around its patented phosphoprotein and protein biomarker platform, complemented by advanced laboratory developed test (LDT) technology. This integrated approach allows Theralink to target multiple critical areas within oncology and drug development, providing highly specific insights into disease mechanisms and treatment efficacy. The core of Theralink's offerings is its Theralink Reverse Phase Protein Array (RPPA) assays. These sophisticated assays are designed to generate precision oncology data, which is crucial for assisting both the biopharmaceutical industry and clinical oncologists. By analyzing protein expression and phosphorylation patterns, the assays help in identifying patients who are likely to respond to various FDA-approved and investigational drug treatments, as well as those who may not benefit. This capability is vital for personalizing cancer therapy, minimizing ineffective treatments, and optimizing patient outcomes. The actionable information derived from Theralink's data-generating assays serves a broad spectrum of stakeholders, including physicians seeking to tailor treatment plans, patients hoping for more effective therapies, and biopharmaceutical companies aiming to refine drug development and clinical trial strategies. The company, originally incorporated as OncBioMune Pharmaceuticals, Inc., underwent a strategic rebranding and name change to Theralink Technologies, Inc. in September 2020, signaling its sharpened focus on its proprietary precision medicine platform and molecular diagnostics in oncology.
What Products and Services Does THER Offer?
- Develops and commercializes novel cancer immunotherapy products.
- Utilizes a patented phosphoprotein and protein biomarker platform.
- Offers Laboratory Developed Test (LDT) technology for oncology and drug development.
- Provides precision oncology data through Theralink Reverse Phase Protein Array (RPPA) assays.
- Assists biopharmaceutical companies in identifying drug responders and non-responders.
- Supports clinical oncologists in personalizing cancer treatment decisions.
- Generates actionable molecular information for physicians, patients, and biopharmaceutical companies.
- Focuses on improving outcomes in the area of oncology through data-driven insights.
How Does THER Make Money?
- Generates revenue by providing precision oncology data services to biopharmaceutical companies for drug development and clinical trials.
- Monetizes its Theralink Reverse Phase Protein Array (RPPA) assays by offering them as laboratory developed tests (LDTs) to clinical oncologists.
- Aims to secure contracts and partnerships with pharmaceutical firms for biomarker identification and patient stratification.
- Focuses on a service-based model, selling access to its proprietary molecular profiling technology and data insights.
- Potential for future revenue streams from licensing its patented platform or developing companion diagnostics.
What Industry Does THER Operate In?
Theralink Technologies, Inc. operates within the dynamic and rapidly expanding Biotechnology industry, specifically targeting the precision medicine and oncology segments. The broader healthcare sector is increasingly shifting towards personalized treatment approaches, driven by advancements in genomic and proteomic profiling. Theralink's patented phosphoprotein and protein biomarker platform positions it directly within this trend, offering molecular data through its Reverse Phase Protein Array assays. This technology addresses the critical need for identifying patient-specific responses to cancer therapies, a market projected to grow significantly as drug developers and clinicians seek to optimize treatment efficacy and reduce adverse events. The competitive landscape includes established diagnostic companies and emerging biotech firms developing similar biomarker-driven solutions. Theralink's differentiation lies in its specific focus on phosphoprotein analysis, which provides unique insights into cellular signaling pathways relevant to cancer progression and drug resistance. Its commercial-stage status indicates active participation in this competitive, innovation-driven market.
Who Are THER's Key Customers?
- Biopharmaceutical industry, including pharmaceutical companies and biotech firms engaged in cancer drug development.
- Clinical oncologists and oncology practices seeking to personalize treatment strategies for their patients.
- Academic research institutions conducting studies in cancer biology and drug mechanisms.
- Patients, indirectly benefiting from more targeted and effective cancer therapies informed by Theralink's data.
- Contract Research Organizations (CROs) supporting clinical trials for oncology drugs.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Theralink Technologies, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Theralink Technologies, Inc. stands at 147.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Theralink Technologies, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Golden, US. The company is led by CEO Michael I. Ruxin. THER has traded publicly since 2010.
THER Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
THER Latest News
No recent news available for THER.
THER Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for THER.
Price Targets
Wall Street price target analysis for THER.
THER MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for THER; grades run from A+ (80-100) to F (below 30).
Leadership: Michael I. Ruxin
CEO
Michael I. Ruxin serves as the CEO of Theralink Technologies, Inc., leading a team of 16 employees. His background is integral to guiding the company's strategic direction in the precision medicine and molecular data sector. As the head of a commercial-stage biotechnology firm, his expertise is crucial in navigating the complexities of cancer immunotherapy product development and the commercialization of advanced diagnostic assays. Ruxin's leadership focuses on leveraging the company's patented phosphoprotein and protein biomarker platform to deliver actionable oncology data to the biopharmaceutical industry and clinical oncologists.
Track Record: Under Michael I. Ruxin's leadership, Theralink Technologies, Inc. has transitioned to a commercial-stage entity, emphasizing its proprietary Theralink Reverse Phase Protein Array assays. He has overseen the company's strategic pivot and name change in September 2020 from OncBioMune Pharmaceuticals, Inc., solidifying its focus on precision oncology. His tenure is marked by the ongoing development and commercialization efforts of novel cancer immunotherapy products and molecular data-generating technologies, aiming to identify drug responders and non-responders.
THER OTC Market Information
Theralink Technologies, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges like NYSE or NASDAQ, which must meet stringent financial and governance standards, OTC Other companies have minimal public disclosure requirements. This tier is typically for companies that are not current in their reporting, are in financial distress, or have not provided adequate public information. Investors face significantly higher risks due to the lack of transparency and regulatory oversight compared to higher OTC tiers like OTCQB or OTCQX, which have more robust reporting standards.
- OTC Tier: OTC Other
- Limited Public Information: The 'Unknown' disclosure status means investors have limited access to current financial statements and operational updates, hindering informed decision-making.
- High Volatility and Illiquidity: OTC Other stocks typically experience extreme price fluctuations and low trading volumes, making it difficult to buy or sell shares without significant price impact.
- Lack of Regulatory Oversight: Companies on the OTC Other tier are subject to minimal regulatory scrutiny compared to major exchanges, increasing the risk of fraud or misleading information.
- Difficulty in Valuation: Without consistent financial reporting and analyst coverage, accurately valuing the company's shares becomes highly speculative.
- Potential for Penny Stock Status: OTC Other stocks are often considered penny stocks, which are prone to pump-and-dump schemes and significant price manipulation.
- Verify the company's current financial statements and operational reports directly from official sources, if available, despite the 'Unknown' status.
- Research any recent news, press releases, or corporate actions that may provide insights into the company's business and financial health.
- Assess the management team's background, experience, and track record, looking for any red flags or signs of past misconduct.
- Investigate the company's intellectual property, patents, and competitive landscape to understand its true market position and potential.
- Examine the company's capital structure, outstanding shares, and any recent dilution events that could impact shareholder value.
- Understand the specific risks associated with the biotechnology industry, including regulatory approvals and clinical trial outcomes.
- Consult with financial and legal professionals experienced with OTC markets before making any investment decisions.
- Commercial-stage operations: The company is actively developing and commercializing products, indicating a functional business beyond just a shell entity.
- Patented technology: Ownership of a patented phosphoprotein and protein biomarker platform suggests genuine innovation and intellectual property.
- Specific product offerings: The Theralink Reverse Phase Protein Array assays are clearly defined products addressing a market need in oncology.
- Clear business description: The company's focus on precision medicine and molecular data in cancer immunotherapy is well-articulated.
- Identified CEO and HQ: The presence of a named CEO, Michael I. Ruxin, and a physical headquarters in Golden, US, provides a degree of corporate structure.
What Investors Ask About Theralink Technologies, Inc. (THER) — Healthcare
What are the key financial metrics and challenges for Theralink Technologies, Inc.?
Theralink Technologies, Inc. exhibits a unique financial profile characteristic of an early-stage biotechnology company. While it boasts a strong gross margin of 79.2%, indicating efficient cost control at the product level, the company currently faces a significant negative profit margin of -5093.6%.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.